GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner

1 year ago

Trial to Assess Multi Cancer Genetic Risk Assessment in General PracticeMELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies…

Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

1 year ago

Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine developmentEvaxion's AI model predicts vaccine efficacy…

Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

1 year ago

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

1 year ago

NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…

MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

1 year ago

MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium and suppressed endogenous PTH(1-84) CARMEL,…

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

1 year ago

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

1 year ago

Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7%…

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

1 year ago

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell ShuttleCollaboration to…